Allow me to share the paragraph that add to my statement of why this could be a buy opportunity! NFA just thinking outloud
$Syros Pharmaceuticals (SYRS.US)$ We are disappointed by this unexpected outcome, especially for people living with AML,” said David A. Roth, M.D., Chief Medical Officer of Syros. “In our prior Phase 2 clinical trial, the doublet combination of tamibarotene and azacitidine delivered a 61% CR/CRi rate in newly diagnosed AML patients with RARA overexpression. This supports our conviction in pursuing a doublet strategy in higher-risk MDS, where we are comparing tamibarotene and azacitidine to azacitidine alone. We remain steadfast in our commitment to delivering tamibarotene for the treatment of HR-MDS and look forward to sharing pivotal data from SELECT-MDS-1 by mid-fourth quarter.”
Syros continues to evaluate tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients with RARA gene overexpression. The SELECT-MDS-1 trial passed a prespecified futility analysis in the first quarter of 2024 and is continuing as planned, with pivotal CR data expected by the middle of the fourth quarter of 2024.
Syros continues to evaluate tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients with RARA gene overexpression. The SELECT-MDS-1 trial passed a prespecified futility analysis in the first quarter of 2024 and is continuing as planned, with pivotal CR data expected by the middle of the fourth quarter of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Yes scaled in on this drop.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Jaguar8 : Very nice! I to started scaling in! Hehehe Great minds right! Well your great mind and my mush Mellon! Hehehe
Arrayfunction : Thank you for pointing this out! Great job at not falling into the trap of missing the forest for the trees!
here's my gist:
If you don't mind me plagiarizing for the sake of other folks who stumble across this post
- Phase 3 trials are exponentially more important than Phase 2 when looking at a company's potential.
- The results of a Phase 3 trial will determine whether or not a company can expect to generate revenue within the next few years. They are the last stop on the train to the FDA approving a drug for sale.
- Positive Phase 2 trial results don't actually guarantee a positive Phase 3 result by any means. Even if they did, Phase 3 studies take years just to run. Once you add in the timelines for data analysis, reporting writing, IRB/advisory meetings, that Phase 2 drug candidate could be 5+ years away from actually making any money.
- In this case, people panic sold after the failure of a Phase 2 study. But as Trytosaveabit is reminding us, they still have a Phase 3 trial that is soon to wrap up. If those results are positive, the share value is going to rocket. A few minutes of critical thinking turns a 80% price drop into an 80% off sale!
But there still is no way to know for sure the phase 3 trial will be positive or if the company will actually reach the market. So always take risk into account!
Trytosaveabit OP Arrayfunction : Very nicely said! And way better than I could have ever even come close to! So yup have at it! I welcome your input / addition to my clumsy explanation! Thank you!
Arrayfunction Trytosaveabit OP : Don't sell yourself short just because I am 2m tall! (I like that pun because it's true
) You just keep things efficient! And do all the hard work while I am over here giving presentations in the remedial class 
Trytosaveabit OP Arrayfunction : Hehehe! You’re too kind but thank you